Home > Result Summaries: Compounds > ondansetron Result Summaries: ondansetron GSKStudy ID Phase Title Summary (Download) 100401 Phase 4 A Multicenter, Randomized, Double Blind, Placebo-Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Intravenous Ondansetron Hydrochloride with Intravenous Dexamethasone Versus Intravenous Ondansetron Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting in Fe ... (0 citation(s)) 100419 Phase 4 A Randomized, Double Blind, Active-Controlled Multicenter Clinical Trial To Evaluate The Anti-Emetic Prophylactic Efficacy Of Ondansetron On Post-Operative Nausea And Vomiting In Patients With Intravenous Patient Controlled Analgesia (2 citation(s)) 112789 N/A Drug Use Investigation for Zofran Syrup (0 citation(s)) 115458 phase 1 A Randomized, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous Ondansetron, a 5-HT3 Antagonist, on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects. (0 citation(s)) 552002 Phase 3 A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis (0 citation(s)) C93-077 Phase 1 A study to investigate the relative bioavailability of ondansetron syrup and Zofran tablets 4 mg (2 citation(s)) GHP:87:19 Phase 1 A Study To Evaluate The Effect Of Repeat Oral Dosing Of GR38032F At 8 Mg BD, 1 Mg BD And 0.25 Mg BD On Cognitive Function In Healthy Volunteers. (0 citation(s)) GHP:87:21 Phase 1 A Study To Evaluate The Effect Of GR38032F On Psychomotor Performance After Repeat Oral Dosing In Healthy Volunteers. (1 citation(s)) GHP:90:19 Phase 1 The Interaction Of Ondansetron And Temazepam. (1 citation(s)) GL/PNV/001 Phase 3 A randomised, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety profile of a single 4mg intravenous bolus dose of ondansetron in the prevention of post-operative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological surgery. (0 citation(s)) GM2006/00037/00 Phase 2 A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of a New Chemical Entity When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dex ... (0 citation(s)) GTH001/92 Phase 3 Comparison of ondansetron and placebo for preventing postoperative nausea and emesis in gastrointestinal tract surgery: a multicenter randomised controlled trial. –Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) GTH001/94 Phase 4 An evaluator-blind, randomised, within-patient comparison of ondansetron given three times daily vs. twice daily with or without dexamathasone vs. metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting in children. (0 citation(s)) K91-007 Phase 1 To compare the bioavailabilities of the clinical trial and production formulations of ondansetron tablets (8 mg) for post-operative nausea and vomiting. (0 citation(s)) NKV10001 Phase 1 An open label, repeat dose, randomized, three period crossover, parallel group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects. (0 citation(s)) NKV100787 phase 1 An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant [GW679769] and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron when Administered in Healthy Adult Subjects (1 citation(s)) ONDA0801 Phase 3 Oral Ondansetron Regimen vs Alizapride Injection and Tablet Regimen in the Prophylaxis of Emesis Induced by Chemotherapy in Breast Cancer (2 citation(s)) RM2006/00520/00 Phase 2 A phase II multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study of the safety and efficacy of a new chemical entity when administered orally in combination with ondansetron hydrochloride and dexamethasone for the prevention of chemotherapy-induced nausea ... (0 citation(s)) S3A-150 Phase 2 An evaluation of the pharmacokinetic properties of intravenous ondansetron in children receiving chemotherapy. (2 citation(s)) S3A-154 Phase 1 An Open Label, Randomized Evaluation of the Pharmacokinetic Properties of Intraveneous and Oral Doses of GR 38032F in Healthy, Elderly Volunteers (1 citation(s)) S3A-155 Phase 1 An evaluation of the effect of chemotherapy on the pharmacokinetics of oral ondansetron (GR38032F). (1 citation(s)) S3A-156 Phase 1 An evaluation of the effects of food and antacid on the absorption of oral ondansetron (GR 38032F). (1 citation(s)) S3A-157 Phase 1 An evaluation of the steady-state pharmacokinetics of ondansetron after 1, 4 and 8 mg oral doses (0 citation(s)) S3A-158 Phase 1 Comparison of the pharmacokinetics of ondansetron (GR38032F) in patients with various degrees of hepatic insufficiency and in normal healthy subjects. (1 citation(s)) S3A161 Phase 1 A randomized, double-blind, placebo-controlled study of the effects of two dose levels of intravenous ondansetron on respiratory depression induced by alfentanil in healthy male volunteers. (1 citation(s)) S3A-166 Phase 1 An evaluation of the pharmacokinetic properties of a single intravenous dose of GR38032 in healthy, adult male volunteers (0 citation(s)) S3A-171 Phase 1 An evaluation of the effect of dosage on the pharmacokinetics of intravenous ondansetron. (0 citation(s)) S3A172 Phase 1 An ascending dose safety and pharmacokinetic evaluation of ondansetron administered as single intravenous bolus doses to healthy male volunteers. (0 citation(s)) S3A173 Phase 1 A dose-proportionality study of ondansetron administered as a single intravenous dose to healthy male volunteers. (0 citation(s)) S3A174 Phase 1 A dose-proportionality study of ondansetron administered as a single oral dose (tablet) to healthy male volunteers. (0 citation(s)) S3A176 Phase 1 Evaluation of the Effects of Cytochrome P-450 Enzyme Inducers (Carbamazepine and Phenytoin) on Ondansetron Pharmacokinetics. (0 citation(s)) S3A179 Phase 1 Pharmacokinetics of 16 mg ondansetron suppository, 8 mg zofran tablet, and 8 mg zofran injection in healthy adult male and female subjects. (0 citation(s)) S3A20005 Phase 2 A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral 16MG BD Ondansetron (GR38032F) in Preventing Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery (0 citation(s)) S3A-237 Phase 2 Treatment of Postoperative Nausea and Vomiting: A Randomized Double-Blind Comparison of Intravenous Ondansetron and Placebo in Female Patients Undergoing Laparoscopic Procedures (1 citation(s)) S3A-241 Phase 2 A Randomized, Double-Blind Comparison of Intravenous Ondansetron and Placebo in the Prevention of Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Procedures (5 citation(s)) S3A242 Phase 2 A Randomized, Double-Blind Comparison of Intravenous Ondansetron and Placebo in the Prevention of Postoperative Nausea and Vomiting in Female Patients Undergoing Inpatient Surgical Procedures (2 citation(s)) S3A-243 Phase 2 Prevention of Postoperative Nausea and Vomiting: A Randomized, Double-blind Study of Intravenous Ondansetron in Female Patients Undergoing Laparoscopic Procedures. (2 citation(s)) S3A-245 Phase 3 Treatment of Postoperative Nausea and Vomiting: A Randomized Double-Blind Study of Intravenous Ondansetron in Patients Undergoing Surgical Procedures on an Outpatient Basis (2 citation(s)) S3A248 Phase 3 Prevention of Postoperative Nausea and Vomiting: A Randomized Double-Blind Study of Intravenous Ondansetron in Female Patients Undergoing Surgical Procedures on an Ambulatory Basis (2 citation(s)) S3A-249 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Study of the Effects of Intravenous Ondansetron on Atracurium-Induced Neuromuscular Blockade in Patients Undergoing Surgical Procedures (1 citation(s)) S3A-255 Phase 2 A Double-Blind, Placebo-Controlled, Dose-Ranging Study of Intravenous Ondansetron in the Treatment of Opioid-Induced Emesis (2 citation(s)) S3A-284 Phase 2 A Double-Blind Dose Comparison of Oral GR-C507/75 in the Prevention of Delayed Nausea and Vomiting Associated With Cisplatin (1 citation(s)) S3A-287 Phase 2 An Open Label Evaluation of Three Different Doses of Oral GR-C507/75 In the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy (1 citation(s)) S3A290 Phase 2 A Randomized, Double-Blind Comparison of Intravenous GR-C507/75 (Ondansetron) and Placebo in the Treatment of Postoperative Nausea and Vomiting (1 citation(s)) S3A-291 Phase 2 A Double-Blind Evaluation of Oral GR-38032F in the Prevention of Delayed Nausea and Vomiting Associated With High-Dose Cisplatin (0 citation(s)) S3A30020 Phase 3 A Randomised, Double-Blind Comparison of Ondansetron Suppository and Oral Ondansetron in the Prevention of Emesis and Nausea Associated with Cyclophosphamide Chemotherapy (0 citation(s)) S3A30023 Phase 3 A Randomised Double-Blind Study to Compare the Efficacy and Safety of Oral GR38032F with Metoclopramide in the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy Regimen(s) Containing Epirubicin and Cyclophosphamide (1 citation(s)) S3A30024 Phase 3 A Multicentre Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Chemotherapy Emesis Induced by FAC/FEC Regimens. (0 citation(s)) S3A30026 Phase 3 A Randomised Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy Regimens Containing Cyclophosphamide in Combination with Doxorubicin or Epirubicin (1 citation(s)) S3A30027 Phase 3 A Multicentre Double-Blind Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute and Delayed Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens (0 citation(s)) S3A30034 Phase 1 The Pharmacokinetics of Ondansetron Following a Single Intravenous Dose in Paediatric Patients Undergoing General Anaesthesia (1 citation(s)) S3A30035 Phase 3 Prevention of Postoperative Nausea and Vomiting: A Randomized, Stratified, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Male Subjects Undergoing Surgical Procedures on an Ambulatory Basis. (1 citation(s)) S3A30036 Phase 3 A Randomised, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Single Intravenous Bolus Dose of Ondansetron 4mg in the Prevention of Postoperative Nausea and Emesis in Patients Having General Anesthesia and Undergoing Day-case Surgery for Inguinal Hern ... (0 citation(s)) S3A30040 Phase 3 A Double-Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of Intravenously Administered Ondansetron In The Prevention Of Post-Operative Nausea And Vomiting In Patients Having General Anaesthesia And Undergoing Major Gynaecological Surgery. (1 citation(s)) S3A30044 Phase 2 A Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Orally Administered Ondansetron 8mg TDS in the Prevention of Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery (1 citation(s)) S3A30045 Phase 2 A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Ondansetron in the Prevention of Post-Operative Nausea and Vomiting in Patients Having General Anaesthesia and Undergoing Major Gynaecological Surgery (2 citation(s)) S3A30049 Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Intravenous Ondansetron for the Treatment of Postoperative Emesis in Pediatric Patients Undergoing Outpatient Surgery (2 citation(s)) S3A30054 Phase 4 A Multicentre, Double-Blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Oral Ondansetron 8mg BD and 16mg OD in the Control of Nausea and Emesis Induced by Cyclophosphamide Containing Chemotherapy in Cancer Patients (0 citation(s)) S3A30055 Phase 4 A Multicentre, Double-Blind, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Oral Ondansetron 8mg BD and 16mg OD in the Control of Nausea and Emesis Induced by Cyclophosphamide Containing Chemotherapy in Breast Cancer Patients (0 citation(s)) S3A30064 Phase 2 A Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Orally Administered Ondansetron 16mg TDS In The Prevention Of Post-Operative Nausea And Vomiting In Patients Having General Anaesthesia And Undergoing Major Gynaecological Surgery. (0 citation(s)) S3A30065 Phase 3 Risk-adapted management of postoperative nausea and postoperative vomiting: a phase III-study to assess safety and efficacy of intravenous ondansetron and oral disintegrating tablets of ondansetron. (2 citation(s)) S3A30067 Phase 3 Ondansetron plus Placebo versus Ondansetron plus Dexamethasone under consideration of a risk score for the prophylaxis of post operative nausea and vomiting (PONV) (2 citation(s)) S3A-351 Phase 3 A Single-Blind Evaluation of Intravenous GR-C507/75 Compared to Intravenous Metoclopramide in the Prevention of Nausea and Vomiting Associated With High-Dose Cisplatin (1 citation(s)) S3A-352 Phase 3 A Randomized Double-Blind Comparison of Three Dose Levels of Intravenous GR-C507/75 (GR 38032F) in the Prevention of Nausea and Vomiting Associated with Cisplatin (1 citation(s)) S3A-354 Phase 3 A Double-Blind Comparison of Intravenous GR-C507/75 (GR38032F) and Placebo in the Prevention of Nausea and Vomiting Associated With Cisplatin or Cyclophosphamide Chemotherapy (0 citation(s)) S3A356 Phase 3 A Double-Blind Evaluation of Three Different Doses of Intravenous GR-C507/75 (Ondansetron) in the Prevention of Nausea and Vomiting Associated With a Multiple Day Regimen of Cisplatin (0 citation(s)) S3A-359 Phase 3 A Randomized Double-Blind Comparison of Three Dose Levels of Intravenous GR-C507/75 in the Prevention of Nausea and Vomiting Associated With Cisplatin (0 citation(s)) S3A362 Phase 3 A Randomized, Double-Blind, Placebo-Controlled Dose Range Evaluation of Oral GR 38032F in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy (0 citation(s)) S3A372 Phase 3 A Double-Blind, Placebo-Controlled Study of Oral Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Female Patients (1 citation(s)) S3A-375 Phase 3 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Oral Ondansetron Administered Twice Daily in the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy (2 citation(s)) S3A-376 Phase 3 A Stratified, Randomized, Double-Blind, Comparison of Oral Ondansetron Administered Twice Daily Versus Three Times Daily in the Prevention of Nausea and Vomiting Associated with Non-Cisplatin Chemotherapy (2 citation(s)) S3A40022 Phase 4 Open-label multicentre-study to evaluate efficacy and tolerability of a novel fast-dissolving formulation of ondansetron to prevent nausea and vomiting after therapy with non-platinum-containing chemotherapy in paediatric patients. (0 citation(s)) S3A40065 Phase 3 A Randomized, Double-Blind, Placebo-Controlled Dose Range Evaluation of Oral GR 38032F in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy (0 citation(s)) S3A40068 Phase 4 Randomised, double-blind, placebo-controlled, multicentre, parallel group study to evaluate the efficacy and safety of a Zofran iv in the prevention of PONV in major gynaecological surgery. (0 citation(s)) S3A40069 Phase 4 Randomised single centre double-blind study to compare the efficacy and safety of a single iv dose of Zofran administered either prior to induction or prior to cessation of anaesthesia in the prevention of PONV in patients having general anaesthesia and undergoing major surgery. (0 citation(s)) S3A40092 Phase 3 A randomized, double blind, parallel group study to compare the efficacy and tolerability of ondansetron vs metoclopramide in the prevention of post-operative nausea and vomiting in patients undergoing ophthalmic surgery (0 citation(s)) S3A40095 Phase 4 An assessment of the effect of schedule and maintenance on the antiemetic efficacy and safety of ondansetron combined with dexamethasone as acute and maintenance therapy in patients receiving moderately emetogenic chemotherapy. (0 citation(s)) S3A40121 Phase 3 A Multicentre Double-Blind Crossover Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens (1 citation(s)) S3A40125 Phase 3 A randomised double-blind multicentre study to compare the clinical efficacy and safety of ondansetron (GR38032) and prochlorperazine in the prophylaxis of nausea and vomiting caused by fractionated radiotherapy (1 citation(s)) S3A40128 Phase 3 A Randomised, Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR38032) Administered as Either a Single IV Dose or a Continuous Infusion Over 24 hours In Acute Cisplatin-induced Emesis (1 citation(s)) S3A40131 Phase 2 An open non-comparative single centre study to assess the efficacy and safety of ondansetron in the prophylaxis of cancer chemotherapy-induced nausea and vomiting in children. (1 citation(s)) S3A40168 Phase 2 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Efficacy and Pharmacokinetic Parameters of Oral Ondansetron in the Prevention of Nausea and Vomiting Associated With Fractionated Total Body Irradiation (0 citation(s)) S3A40169 Phase 1 An Open-Label Evaluation of Ondansetron Versus Ondansetron Plus Dexamethasone and Chlorpromazine in the Prevention of Nausea and Vomiting Associated with Multiple-Day Cisplatin Chemotherapy (1 citation(s)) S3A40175 Phase 4 A single blind, placebo-controlled, multicentre study of intravenous ondansetron in the prevention of post-operative emesis (retching and vomiting) in paediatric patients undergoing strabismus surgery. (0 citation(s)) S3A40181 Phase 3 A Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Non-Cisplatin Chemotherapy (0 citation(s)) S3A40182 Phase 3 A Stratified, Randomized, Double-Blind Comparison of Intravenous Ondansetron Administered as a Multiple Dose Regimen Versus Two Single Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting (1 citation(s)) S3A40206 Phase 3 A double-blind, placebo-controlled multicentre study of intravenous ondansetron in the prevention of post-operative emesis (retching and vomiting) in paediatric patients undergoing strabismus surgery (0 citation(s)) S3A40231 Phase 4 A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery (2 citation(s)) S3A40232 Phase 4 An Open-Label Study of IV Ondansetron Plus Dexamethasone for the Prevention of Emesis Associated with Different Degrees of Emetogenic Chemotherapy (0 citation(s)) S3A40240 Phase 4 A randomised, double-blind, parallel group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. (2 citation(s)) S3A40241 Phase 4 A Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Safety of Ondansetron plus Dexamethasone, Ondansetron and Tropisetron in the Control of Acute Cisplatin-induced Nausea and Emesis (0 citation(s)) S3A40262 Phase 3 A randomized, double-blind, placebo-controlled, multi-center study of intravenous ondansetron for the prevention of postoperative emesis in pediatric patients undergoing outpatient surgery. (2 citation(s)) S3A40275 Phase 4 A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ondansetron Versus Droperidol for the Prevention of Postoperative Nausea and Vomiting in Outpatient Surgery. (2 citation(s)) S3A40284 Phase 4 A randomised double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of a single intravenous dose of Ondansetron in the prevention of post-operative nausea and emesis in paediatric patients having general anaesthesia and undergoing surgery for tonsillectomy with o ... (2 citation(s)) S3A40317 Phase 3 A randomised, double-blind, placebo-controlled multicentre parallel-group study to compare the efficacy and safety of a single intravenous bolus dose of ondansetron, metoclopramide and placebo in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergo ... (3 citation(s)) S3A40318 Phase 3 A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of single doses of orally administered ondansetron in the prevention of post-operative nausea and vomiting in patients having general anaesthesia and undergoing major gynaecological surgery (0 citation(s)) S3A40319 Phase 4 A Phase IV, Multi-Center, Two-Arm, Single-Dose Pharmacokinetic Study of Intravenous ZOFRAN in Pediatric Surgical Patients from 1 Month to 24 Months of Age (3 citation(s)) S3A40320 Phase 4 An Open-label, Multicenter, Study of the Safety and Antiemetic Effect of 0.15 mg/kg Intravenous Ondansetron Hydrochloride Administered for Three Doses to Pediatric Cancer Patients Aged 6 Months to 48 Months Who Are Receiving Moderately to Highly Emetogenic Chemotherapy (0 citation(s)) S3A40323 Phase 3 A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Intravenous Ondansetron Hydrochloride 0.1 mg/kg for the Prevention of Postoperative Emesis in Pediatric Surgical Subjects Ages 1 Month to 24 Months Who Are Undergoing Routine Surgery Under General Anesthesia. (2 citation(s)) S3AA1002 Phase 1 A Bioequivalence Study Comparing Three 8-mg Zofran® Tablets to a Single 24-mg Ondansetron Tablet (0 citation(s)) S3AA1003 Phase 1 Dose-Response Effects of Ondansetron vs. Placebo on Morphine-Induced Nausea, Gastric Dysrhythmias and Plasma Vasopressin (1 citation(s)) S3AA3004 Phase 3 A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated With Moderately-High Emetogenic Chemotherapy (1 citation(s)) S3AA3012 Phase 3 A Randomized, Double-Blind Study of Oral Ondansetron, 8mg Twice Daily, 24mg Once Daily and 32mg Once Daily, in the Prevention of Nausea and Vomiting Associated With Cisplatin Chemotherapy (1 citation(s)) S3AA3013 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Single Dose Ondansetron 8mg and Single Dose Ondansetron 16mg for the Treatment of Opioid-Induced Nausea and Emesis in Subjects Experiencing Acute Pain (1 citation(s)) S3AA4001 Phase 4 A Multicenter Study to Evaluate the Efficacy and Safety of a Repeat Dose of Ondansetron in Ambulatory Surgery Patients who do not Achieve Adequate Control of Postoperative Nausea and Vomiting Following Prophylaxis With Open-Label Intravenous Ondansetron (1 citation(s)) S3AA4002 Phase 4 A Randomized, Double-Blind Comparison of Single-Dose Intravenous Ondansetron Versus Single-Dose Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin Chemotherapy (1 citation(s)) S3AA4003 Phase 4 A Stratified, Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine® Spansules® in the Prevention of Nausea and Vomiting Associated With Moderately-Emetogenic Chemotherapy (0 citation(s)) S3AB3003 Phase 3 A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Compare the Efficacy and Safety of Intravenous Doses of Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis in Patients Undergoing Elective Major Abdominal Surgery (0 citation(s)) S3AB3004 Phase 3 A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Intravenous Ondansetron 4mg and 8mg in the Prevention of Postoperative Nausea and Emesis In-Patients Undergoing Major Gynaecological Surgery (0 citation(s)) S3AB3005 Phase 3 A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron 8mg bd Tablet and Ondansetron ZYDIS™ 8mg bd in the Control of Emesis and Nausea Induced by Cyclophosphamide-Containing Chemotherapy Treatment in Cancer Patients (0 citation(s)) S3AB3006 Phase 3 A multicentre, double-blind, randomised, parallel group study to compare the efficacy and safety of two ondansetron regimens in the control of emesis and nausea induced by cancer chemotherapy in paediatric patients. (1 citation(s)) S3AB3008 Phase 3 A multicentre, double-blind, double-dummy, parallel group study to compare the efficacy and safety of intravenous ondansetron 8mg plus intravenous dexamethasone 20mg with oral ondansetron 24mg od plus oral dexamethasone 12mg od in the control of acute emesis and nausea induced by cisplatin chemo ... (0 citation(s)) S3AC01 Phase 3 A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective orthopaedic ... (0 citation(s)) S3AM23 Phase 3 A Multicentre Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR 38032F) Administered Either as a Single Intravenous Dose or a Continuous Infusion in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-containing Cancer Chemotherapy Regimens (1 citation(s)) S3AP31 Phase 3 To Compare the Efficacy and Safety of Ondansetron with Dexamethasone in the Prophylaxis of Nausea and Vomiting Induced by Non-Platinum-Containing Cancer Chemotherapy Regimens (1 citation(s)) S3AP36 Phase 2 A Multi-Centre Study to Assess the Clinical Efficacy and Safety of GR38032F in the Prophylaxis of Cisplatin-Induced Nausea and Vomiting (0 citation(s)) S3AP47 Phase 4 A Pilot Study to Determine the Optimal Dose, Tolerance and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Maintenance Therapy Used in Children with Acute Lymphoblastic Leukaemia (0 citation(s)) S3AP48 Phase 1 A Pilot Study to Determine the Safety and Efficacy of Ondansetron (GR38032F) in the Prevention of Nausea and Vomiting Induced by Cancer Chemotherapy Regimens Containing Cisplatin, Carboplatin or Doxorubicin in Combination with either Cyclophosphamide or Ifosfamide in Children (0 citation(s)) S3AP54 Phase 1 The pharmacokinetics of oral ondansetron (GR38032F) in elderly patients receiving cytotoxic chemotherapy or radiotherapy. (1 citation(s)) S3AT03 Phase 3 A Randomised Double-Blind Multicentre Study to Compare the Clinical Efficacy and Safety of Ondansetron (GR38032F) and Metoclopramide in the Prophylaxis of Single Fraction Radiotherapy-Induced Nausea and Vomiting (2 citation(s)) S3AT07 Phase 2 A Randomised, Double-Blind, Placebo Controlled Study Of The Efficacy And Safely Of Ondansetron (GR38032F) in The Prophylaxis Of Nausea And Vomiting Induced By The Combination Of Cyclophosphamide, Doxorubicin And Prednisolone With Vincristine (CHOP), VP16 Or VM26 (0 citation(s)) S3AT17 Phase 2 A Randomised Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Ondansetron Given Orally 8mg Three Times A Day in the Prophylaxis of Nausea and Vomiting Induced by the Combination of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Women with Breast Cancer (1 citation(s)) S3AT20 Phase 3 Comparison of Ondansetron vs Ondansetron + Dexamethasone in the control of delayed emesis and nausea induced by Cisplatin. (1 citation(s)) S3AV01 Phase 3 A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective abdominal su ... (0 citation(s)) S3AV02 Phase 3 A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological ... (0 citation(s)) S3GK01 Phase 1 A Study to Determine the Pharmacokinetics of Orally Administered Ondansetron 16mg in Patients Having Surgery Under General Anaesthesia (0 citation(s)) TP552001 Phase 3 A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis. (0 citation(s)) TP552002 Phase 3 A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis. (0 citation(s)) UCP-95-053 Phase 1 An Evaluation of Relative Bioavailability of Ondansetron From an 8mg Zydis® Formulation and an 8mg Zofran® Tablet (0 citation(s)) W91-016 Phase 1 The Pharmacokinetics and Tolerability of Ondansetron 4mg Given as an Intramuscular Injection (1 citation(s)) WHP:87:12, WHP:88:12 Phase 1 Radioisotope Study To Investigate The Metabolic Disposition Of GR38032 In Man (0 citation(s)) WHP:89:26 Phase 1 A Study Of The Cardiovascular Effects Of Intravenous GR38032F 16 Mg In Healthy Volunteers (0 citation(s)) ZOF-011/2002 Phase 4 Open label treatment observational cohort (TOC) of a Single Dose Therapy with Zofran for the Prevention and Therapy of Chemotherapy-induced Nausea and Emesis (CINV) (0 citation(s))
